ViMRT
}  
 
Home   
< Docs   

 HIV mutation literature information.


  Brazilian Network for HIV Drug Resistance Surveillance (HIV-BResNet): a survey of chronically infected individuals.
 PMID: 12700457       2003       AIDS (London, England)
Abstract: Mutations known to be associated with reduced sensitivity to NRTI or NNRTI (V118I, E44D, K219R, T69A, and V75L) were found in a low prevalence (0.6-2.4%).


  Broad nucleoside-analogue resistance implications for human immunodeficiency virus type 1 reverse-transcriptase mutations at codons 44 and 118.
 PMID: 11920313       2002       The Journal of infectious diseases
Abstract: As expected, E44A/D and V118I mutations were strongly associated with M41L, D67N, L210W, and T215Y but also with other mutations, including K43E/N/Q, T69D, V75M, H208Y, R211K, and K219R.
Abstract: Both E44D and V118I were more frequently associated with stavudine and didanosine than with zidovudine and lamivudine treatment.
Abstract: However, selection of E44A/D and V118I was also detected in associa


  Mutations E44D and V118I in the reverse transcriptase of HIV-1 play distinct mechanistic roles in dual resistance to AZT and 3TC.
 PMID: 11793380       2002       Journal of medical virology
Abstract: A relationship was found between the E44D/A and/or V118I mutational pattern and experience with didanosine or stavudine but not with lamivudine.
Abstract: It has been reported that a new pattern of mutations, E44D/A and/or V118I, in the reverse transcriptase (RT) gene of HIV-1 confers a moderate level of resistance to lamivudine in the absence of the M184V mutation.
Abstract: Multivariate analysis showed an association between the E44D/A and/or V118I mutational pattern and the RT mutations D67N, T69D, L210W,


  Mutations E44D and V118I in the reverse transcriptase of HIV-1 play distinct mechanistic roles in dual resistance to AZT and 3TC.
 PMID: 11181387       2001       Antimicrobial agents and chemotherapy
Abstract: Recently, it has been shown that a new mutational pattern (the E44D/A and/or V118I mutation) confers moderate phenotypic lamivudine resistance in the absence of the M184V mutation.
Abstract: The E44D/A and/or the V118I mutation does not exist in drug-naive patients, and the prevalence increases with the number of treatment regimens and lamivudine experience.



Browser Board

 Co-occurred Entities




   Filtrator